ClinicalTrials.gg
Active, not recruitingNCT06534892RSV OA=ADJ=012Updated Oct 1, 2026

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

A Phase 3 interventional study of RSVPreF3 OA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Active, not recruiting at 251 sites in 17 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Updated Oct 1, 202622 sites added20 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,212
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
2nd of 17
10,212 · median 976
Started
2024
with 6 others
Phase 3
15 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 2nd largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 12th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of this study is:

  • To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose,
  • To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine,
  • To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus (RSV)
  • Older adults
  • RSVPreF3 OA vaccine
  • Immunogenicity
  • Safety
  • RSV Season
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants who were previously enrolled in the RSV OA=ADJ-006 study and received placebo (Placebo group) or a single dose of the RSVPreF3 OA vaccine (RSV_1dose group).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, attend regular phone calls/study site visits, ability to access and utilize a phone or other electronic communications).
  • Written or witnessed obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at study entry. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study.

Exclusion criteria

Exclusion Criteria:

Medical Conditions:

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by any component of the study intervention.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Recurrent or un-controlled neurological disorders or seizures.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any other medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition and understanding of the form and/or study procedures.
  • Participants who experienced an SAE or pIMD from first study intervention administration in the RSV OA=ADJ-006 study until enrollment in this study that was considered to be possibly or probably related to the study vaccine or non-study concomitant vaccines, either by the investigator or the sponsor, including hypersensitivity reactions.
  • Participants with a new onset of a pIMD or exacerbation of a pIMD from first study intervention administration in the RSV OA=ADJ-006 study until enrollment in this study, that, in the opinion of the investigator, exposes the participant to unacceptable risk from subsequent vaccination.

Prior/Concomitant Therapy:

  • Use of any or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period. • Previous vaccination with an RSV vaccine (investigational or licensed vaccine) and/or planned administration of an RSV vaccine during the study period other than the RSVPreF3 OA vaccine administered during the RSV OA=ADJ-006 study.

Prior/Concurrent Clinical Study Experience:

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other Exclusion Criteria:

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Participation of any study personnel or their immediate dependents, family, or household members.
  • Bedridden participants.

Specific exclusion criteria for Crossover group:

  • Planned or administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after study intervention administration, with the exception of COVID vaccines which can be administered up to 14 days before or from 14 days after study vaccination. Inactivated seasonal influenza vaccines can be co-administered or administered at any time.

Specific exclusion criteria for RSV_PreS4, RSV_PreS5 and RSV_1Dose groups:

  • Planned or administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after study intervention administration, with the exception of COVID vaccines and inactivated seasonal influenza vaccines which can be administered up to 14 days before or from 14 days after study intervention administration.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first study visit or planned administration during the study period.
  • Chronic administration of immunosuppressants or other immunemodifying drugs during the period starting 90 days prior to the first study visit or planned administration during the study period. For , this will mean prednisone >= 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10,212 participants (actual)

Study arms

  • Experimental
    RSV_PreS4

    Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 4.

    Biological: RSVPreF3 OA vaccine

  • Experimental
    RSV_PreS5

    Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 5.

    Biological: RSVPreF3 OA vaccine

  • No intervention
    RSV_1Dose

    Participants in this group will not receive any additional dose of RSV PreF3 OA vaccine.

  • Experimental
    Crossover

    Participants in this group will receive a single dose of RSVPreF3 OA vaccine.

    Biological: RSVPreF3 OA vaccine

Interventions

  • RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)

06

What researchers measure

Primary outcomes

  1. RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) in RSV_PreS4 group at Day 1

    Time frame: At Day 1

  2. RSV-A neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31

    Time frame: At Day 31

  3. RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 1

    Time frame: At Day 1

  4. RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31

    Time frame: At Day 31

  5. RSV-A neutralizing titers expressed as Mean geometric increase (MGI) in RSV_PreS4 group

    Time frame: From Day 1 to Day 31

  6. RSV-B neutralizing titers expressed as MGI in RSV_PreS4 group

    Time frame: From Day 1 to Day 31

  7. Percentage of participants with RSV-A neutralizing titers greater than or equal to (>=) cut-off in RSV_PreS4 group at Day 1

    Time frame: At Day 1

  8. Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_PreS4 group at Day 31

    Time frame: At Day 31

  9. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 1

    Time frame: At Day 1

  10. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 31

    Time frame: At Day 31

  11. Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS4 group

    Time frame: At Day 31

  12. Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS4 group

    Time frame: At Day 31

  13. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Day 1

    Time frame: At Day 1

  14. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 12

    Time frame: At Month 12

  15. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 13

    Time frame: At Month 13

  16. RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 24

    Time frame: At Month 24

  17. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Day 1

    Time frame: At Day 1

  18. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 12

    Time frame: At Month 12

  19. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 13

    Time frame: At Month 13

  20. RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 24

    Time frame: At Month 24

  21. RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13

    Time frame: From Month 12 to Month 13

  22. RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24

    Time frame: From Month 12 to Month 24

  23. RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13

    Time frame: From Month 12 to Month 13

  24. RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24

    Time frame: From Month 12 to Month 24

  25. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Day 1

    Time frame: At Day 1

  26. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 12

    Time frame: At Month 12

  27. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 13

    Time frame: At Month 13

  28. Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 24

    Time frame: At Month 24

  29. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Day 1

    Time frame: At Day 1

  30. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 12

    Time frame: At Month 12

  31. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 13

    Time frame: At Month 13

  32. Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 24

    Time frame: At Month 24

  33. Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS5 group

    Time frame: At Month 13

  34. Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS5 group

    Time frame: At Month 13

Secondary outcomes

  1. RSV-A neutralizing titers expressed as GMTs in RSV_1Dose group

    Time frame: At Day 1, Month 12 and at Month 24

  2. RSV-B neutralizing titers expressed as GMTs in RSV_1Dose group

    Time frame: At Day 1, Month 12 and at Month 24

  3. Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_1Dose group

    Time frame: At Day 1, Month 12 and at Month 24

  4. Percentage of participants with RSV-B neutralizing titers >= cut-off in RSV_1Dose group

    Time frame: At Day 1, Month 12 and at Month 24

  5. Number of participants with unsolicited adverse events

    Time frame: At Day 30 post vaccination

  6. Number of participants with any serious adverse events (SAEs)

    Time frame: From day of vaccination and up to 6 months post each vaccine administration

  7. Number of participants with SAEs related to study intervention

    Time frame: From Day 1 and up to end of study

  8. Number of participants with any potential immune-mediated disease (pIMDs)

    Time frame: From day of vaccination and up to 6 months post each vaccine administration

  9. Number of participants with pIMDs related to study intervention

    Time frame: From Day 1 and up to end of study

  10. Number of participants with fatal SAEs

    Time frame: From Day 1 and up to end of study

07

Study locations

251 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Birmingham, Alabama 35211, United States
  • GSK Investigational Site
    Huntsville, Alabama 35802, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Cerritos, California 90703, United States
  • GSK Investigational Site
    Doral, Florida 33172-2513, United States
  • GSK Investigational Site
    Fort Myers, Florida 33912-4316, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Lake City, Florida 32055, United States
  • GSK Investigational Site
    Melbourne, Florida 32934-8172, United States
  • GSK Investigational Site
    Miami, Florida 33174, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Pinellas Park, Florida 33781, United States
  • GSK Investigational Site
    The Villages, Florida 32162, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Atlanta, Georgia 30328, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Chicago, Illinois 60602, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Mishawaka, Indiana 46544, United States
  • GSK Investigational Site
    El Dorado, Kansas 67042-2187, United States
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Wichita, Kansas 67205-1132, United States
  • GSK Investigational Site
    Wichita, Kansas 67226, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Rockville, Maryland 20854, United States
  • GSK Investigational Site
    Richfield, Minnesota 55423, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    New York, New York 10017, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Mooresville, North Carolina 28117, United States
  • GSK Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103-3914, United States
  • GSK Investigational Site
    Centerville, Ohio 45459, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Columbus, Ohio 43212, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Anderson, South Carolina 29621, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29405, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37938, United States
  • GSK Investigational Site
    Memphis, Tennessee 38119, United States
  • GSK Investigational Site
    Dallas, Texas 75234, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77008, United States
  • GSK Investigational Site
    Keller, Texas 76248, United States
  • GSK Investigational Site
    San Antonio, Texas 78229-6306, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84106, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Botany, New South Wales 2019, Australia
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Taringa, Queensland 4068, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Spearwood, Western Australia 6163, Australia
  • GSK Investigational Site
    Diepenbeek, Limburg 3590, Belgium
  • GSK Investigational Site
    Ghent, Oost-Vlaanderen 9000, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Ieper, 8900, Belgium
  • GSK Investigational Site
    Kluisbergen, 9690, Belgium
  • GSK Investigational Site
    Linkebeek, 3545, Belgium
  • GSK Investigational Site
    Linkebeek, 6534, Belgium
  • GSK Investigational Site
    Mechelen, 2800, Belgium
  • GSK Investigational Site
    Namur, 5101, Belgium
  • GSK Investigational Site
    Tremelo, 3120, Belgium
  • GSK Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • GSK Investigational Site
    New Westminster, British Columbia V3L 3W4, Canada
  • GSK Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 4A1, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3J 3G9, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Greater Sudbury, Ontario P3C 1X3, Canada
  • GSK Investigational Site
    London-Ontario, Ontario N5W 6A2, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Chicoutimi, Quebec G7H 7Y8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R4S3, Canada
  • GSK Investigational Site
    Québec, Quebec G1W 4R4, Canada
  • GSK Investigational Site
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Paide, 72713, Estonia
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tallinn, 10128, Estonia
  • GSK Investigational Site
    Tallinn, 10617, Estonia
  • GSK Investigational Site
    Tallinn, 13619, Estonia

Showing the first 100 of 251 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's planned 25 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
22 sites added, 20 sites removed
Show 22 added (6 Germany, 5 Spain, 5 United Kingdom, 3 Belgium, 1 United States, 1 Italy, 1 South Africa)
  • GSK Investigational Site · San Antonio, United States
  • GSK Investigational Site · Diepenbeek, Belgium
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Namur, Belgium
  • GSK Investigational Site · Dachau, Germany
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Cologne, Germany
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Goch, Germany
  • GSK Investigational Site · Leipzig, Germany
  • GSK Investigational Site · Negrar, Italy
  • GSK Investigational Site · Santiago de Compostela, Spain
  • GSK Investigational Site · Centelles, Spain
  • GSK Investigational Site · Vic, Spain
  • GSK Investigational Site · Majadahonda, Spain
  • GSK Investigational Site · Valencia, Spain
  • GSK Investigational Site · Orpington, United Kingdom
  • GSK Investigational Site · Bellshill, United Kingdom
  • GSK Investigational Site · Metropolitan Borough of Wirral, United Kingdom
  • GSK Investigational Site · Witney, United Kingdom
  • GSK Investigational Site · Bradford on Avon, United Kingdom
  • GSK Investigational Site · Ekurhuleni, South Africa
Show 20 removed
  • GSK Investigational Site · Diepenbeek, Belgium
  • GSK Investigational Site · Erpent, Belgium
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Cologne, Germany
  • GSK Investigational Site · Dachau, Germany
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Goch, Germany
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Leipzig, Germany
  • GSK Investigational Site · Negrar Verona, Italy
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Barcelona, Spain
  • GSK Investigational Site · Madrid, Spain
  • GSK Investigational Site · Santiago de Compostela, Spain
  • GSK Investigational Site · Bebington, United Kingdom
  • GSK Investigational Site · Bradford on Avon Wiltsh, United Kingdom
  • GSK Investigational Site · Eynsham, United Kingdom
  • GSK Investigational Site · Glasgow, United Kingdom
  • GSK Investigational Site · Orpington, United Kingdom
  • GSK Investigational Site · Ekurhuleni, South Africa
across 2 updates, Sep 28, 2026 – Oct 1, 2026
Show all 2 updates
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · Ekurhuleni, South Africa
    Show 1 removed
    • GSK Investigational Site · Ekurhuleni, South Africa
  2. Sep 28, 2026
    21 sites added, 19 sites removed
    Show 21 added (6 Germany, 5 Spain, 5 United Kingdom, 3 Belgium, 1 United States, 1 Italy)
    • GSK Investigational Site · San Antonio, United States
    • GSK Investigational Site · Diepenbeek, Belgium
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Namur, Belgium
    • GSK Investigational Site · Dachau, Germany
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Cologne, Germany
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Goch, Germany
    • GSK Investigational Site · Leipzig, Germany
    • GSK Investigational Site · Negrar, Italy
    • GSK Investigational Site · Santiago de Compostela, Spain
    • GSK Investigational Site · Centelles, Spain
    • GSK Investigational Site · Vic, Spain
    • GSK Investigational Site · Majadahonda, Spain
    • GSK Investigational Site · Valencia, Spain
    • GSK Investigational Site · Orpington, United Kingdom
    • GSK Investigational Site · Bellshill, United Kingdom
    • GSK Investigational Site · Metropolitan Borough of Wirral, United Kingdom
    • GSK Investigational Site · Witney, United Kingdom
    • GSK Investigational Site · Bradford on Avon, United Kingdom
    Show 19 removed
    • GSK Investigational Site · Diepenbeek, Belgium
    • GSK Investigational Site · Erpent, Belgium
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Cologne, Germany
    • GSK Investigational Site · Dachau, Germany
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Goch, Germany
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Leipzig, Germany
    • GSK Investigational Site · Negrar Verona, Italy
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Barcelona, Spain
    • GSK Investigational Site · Madrid, Spain
    • GSK Investigational Site · Santiago de Compostela, Spain
    • GSK Investigational Site · Bebington, United Kingdom
    • GSK Investigational Site · Bradford on Avon Wiltsh, United Kingdom
    • GSK Investigational Site · Eynsham, United Kingdom
    • GSK Investigational Site · Glasgow, United Kingdom
    • GSK Investigational Site · Orpington, United Kingdom
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06534892
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Aug 1, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion